2024-10-07 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison:**

Eli Lilly and Co. (LLY) has significantly outperformed the S&P 500 (VOO) in terms of cumulative returns. 

* **LLY Cumulative Return:** 851.72%
* **VOO Cumulative Return:** 133.14%
* **Difference:** 718.58% 
* **Relative Divergence:** 89.27% (This indicates that LLY's performance is currently at the 89.27th percentile of its historical performance relative to VOO.)

**2. Recent Price Movements:**

* **Closing Price:** $887.16
* **5-Day Moving Average:** $886.84
* **20-Day Moving Average:** $907.05
* **60-Day Moving Average:** $895.35

The stock price is currently below its 20-day and 60-day moving averages, suggesting potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 33.45 (Suggests the stock is in oversold territory)
* **PPO:** -0.46 (Indicates a downward trend)
* **Delta_Previous_Relative_Divergence:** -4.01 (Suggests a short-term downtrend)
* **Expected Return:** 6.72% (This is a 5-year expected return over the S&P 500, based on current investment amount)

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue    |
|------------|--------|------------|
| 2024-08-08 | 3.29   | 11.30 B$   |
| 2024-04-30 | 2.49   | 8.77 B$    |
| 2023-11-02 | -0.06  | 9.50 B$    |
| 2023-08-08 | 1.96   | 8.31 B$    |
| 2024-08-08 | 1.96   | 8.31 B$    |

The most recent earnings report (2024-08-08) showed an EPS of 3.29, exceeding analysts' expectations by 0.24. Revenue also exceeded estimates, coming in at 11.30 B$. This strong performance reflects Eli Lilly's continued success in its core pharmaceutical business. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** Eli Lilly is a leading pharmaceutical company with a strong track record of innovation and growth. The company's pipeline is robust, with several promising new drug candidates in development. This suggests that Eli Lilly is well-positioned for continued long-term growth. However, the company faces potential risks from increased competition and pricing pressure in the pharmaceutical industry.
* **Analyst Opinions:** Most analysts have a positive outlook for Eli Lilly, with many rating the stock as a "buy" or "strong buy."
* **Performance Highlights:** Eli Lilly has consistently outperformed the S&P 500 in recent years. This is driven by strong sales of its existing products, as well as the successful launch of new drugs. 

**6. Comprehensive Analysis:**

Eli Lilly and Co. (LLY) remains a strong performer in the pharmaceutical industry. The company has a solid track record of growth and innovation, and its pipeline suggests continued long-term potential. Although the stock is currently trading below its moving averages and technical indicators suggest a short-term downtrend, the strong earnings report and positive analyst sentiment indicate a favorable outlook for LLY. 

**7. Conclusion:**

While the recent price movements and technical indicators suggest a short-term correction, Eli Lilly's solid financial performance, robust pipeline, and favorable market outlook suggest potential for future growth. Investors may consider monitoring the stock for a potential entry point in the coming months.
